Company Filing History:
Years Active: 2010
Title: Atsuchi Imaizumi: Innovator in Humanized Antibodies
Introduction
Atsuchi Imaizumi is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies. His work focuses on addressing the toxic effects of verotoxin II, a potent toxin that poses serious health risks.
Latest Patents
Imaizumi holds a patent for "Humanized antibodies that recognize Verotoxin II and cell line producing same." This invention provides humanized antibodies that specifically bind to and neutralize verotoxin II (VT2). The antibodies are particularly useful for treating patients who are suffering from or at risk of experiencing the toxic effects of verotoxin. He has 1 patent to his name.
Career Highlights
Throughout his career, Atsuchi Imaizumi has worked with prominent companies in the biotechnology sector. Notably, he has been associated with Teijin Limited and PDL BioPharma, Inc. His experience in these organizations has contributed to his expertise in developing innovative solutions in the field.
Collaborations
Imaizumi has collaborated with several professionals in his field, including Yoh-Ichi Matsumoto and Tsuyoshi Kimura. These collaborations have further enhanced his research and development efforts.
Conclusion
Atsuchi Imaizumi is a distinguished inventor whose work on humanized antibodies has the potential to significantly impact the treatment of verotoxin-related health issues. His contributions to biotechnology continue to pave the way for innovative medical solutions.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.